Australian biotech company launched with AU$7m investment to develop therapies for treating obesity

February 19, 2018

Cincera Therapeutics Pty Ltd (“Cincera”) has launched with an AU$7 million venture capital commitment from the Medical Research Commercialisation Fund (MRCF).

The Company has been founded to develop new therapies to target conditions relating to an unhealthy Western diet, including serious and highly prevalent diseases associated with obesity. The company will initially focus on treatments for the emerging epidemic of a liver disease termed ‘NASH’ (non-alcoholic steatohepatitis).